How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy

for the Movement Disorder Society-endorsed PSP Study Group

Research output: Contribution to journalArticle

Abstract

Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. Conclusions: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy.

Original languageEnglish (US)
Pages (from-to)1228-1232
Number of pages5
JournalMovement Disorders
Volume34
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Progressive Supranuclear Palsy
Movement Disorders
Autopsy

Keywords

  • autopsy
  • diversity
  • phenotype
  • progressive supranuclear palsy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. / for the Movement Disorder Society-endorsed PSP Study Group.

In: Movement Disorders, Vol. 34, No. 8, 01.01.2019, p. 1228-1232.

Research output: Contribution to journalArticle

for the Movement Disorder Society-endorsed PSP Study Group 2019, 'How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy', Movement Disorders, vol. 34, no. 8, pp. 1228-1232. https://doi.org/10.1002/mds.27666
for the Movement Disorder Society-endorsed PSP Study Group. / How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. In: Movement Disorders. 2019 ; Vol. 34, No. 8. pp. 1228-1232.
@article{f06e1f25488c4237bd29750e71ccd0c9,
title = "How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy",
abstract = "Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5{\%}). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3{\%}), and the allocations per patient to 1.1. Conclusions: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy.",
keywords = "autopsy, diversity, phenotype, progressive supranuclear palsy",
author = "{for the Movement Disorder Society-endorsed PSP Study Group} and Grimm, {Max Joseph} and Gesine Respondek and Maria Stamelou and Thomas Arzberger and Leslie Ferguson and Ellen Gelpi and Armin Giese and Murray Grossman and Irwin, {David J.} and Alexander Pantelyat and Alex Rajput and Sigrun Roeber and {van Swieten}, {John C.} and Claire Troakes and Angelo Antonini and Bhatia, {Kailash P.} and Carlo Colosimo and {van Eimeren}, Thilo and Jan Kassubek and Johannes Levin and Meissner, {Wassilios G.} and Christer Nilsson and Oertel, {Wolfgang H.} and Ines Piot and Werner Poewe and Wenning, {Gregor K.} and Adam Boxer and Golbe, {Lawrence I.} and Josephs, {Keith A.} and Irene Litvan and Morris, {Huw R.} and Whitwell, {Jennifer L.} and Yaroslau Compta and Corvol, {Jean Christophe} and Lang, {Anthony E.} and Rowe, {James B.} and H{\"o}glinger, {G{\"u}nter U.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/mds.27666",
language = "English (US)",
volume = "34",
pages = "1228--1232",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy

AU - for the Movement Disorder Society-endorsed PSP Study Group

AU - Grimm, Max Joseph

AU - Respondek, Gesine

AU - Stamelou, Maria

AU - Arzberger, Thomas

AU - Ferguson, Leslie

AU - Gelpi, Ellen

AU - Giese, Armin

AU - Grossman, Murray

AU - Irwin, David J.

AU - Pantelyat, Alexander

AU - Rajput, Alex

AU - Roeber, Sigrun

AU - van Swieten, John C.

AU - Troakes, Claire

AU - Antonini, Angelo

AU - Bhatia, Kailash P.

AU - Colosimo, Carlo

AU - van Eimeren, Thilo

AU - Kassubek, Jan

AU - Levin, Johannes

AU - Meissner, Wassilios G.

AU - Nilsson, Christer

AU - Oertel, Wolfgang H.

AU - Piot, Ines

AU - Poewe, Werner

AU - Wenning, Gregor K.

AU - Boxer, Adam

AU - Golbe, Lawrence I.

AU - Josephs, Keith A.

AU - Litvan, Irene

AU - Morris, Huw R.

AU - Whitwell, Jennifer L.

AU - Compta, Yaroslau

AU - Corvol, Jean Christophe

AU - Lang, Anthony E.

AU - Rowe, James B.

AU - Höglinger, Günter U.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. Conclusions: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy.

AB - Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. Conclusions: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy.

KW - autopsy

KW - diversity

KW - phenotype

KW - progressive supranuclear palsy

UR - http://www.scopus.com/inward/record.url?scp=85067853775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067853775&partnerID=8YFLogxK

U2 - 10.1002/mds.27666

DO - 10.1002/mds.27666

M3 - Article

C2 - 30884545

AN - SCOPUS:85067853775

VL - 34

SP - 1228

EP - 1232

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 8

ER -